ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH
October 21, 2020Akero Therapeutics, Inc. announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to efruxifermin (EFX), an investigational FGF21 analog for the treatment of NASH. -
Akero Therapeutics Initiates AKR-001 Phase 2a Clinical Trial for NASH
May 30, 2019Akero Therapeutics announced it has screened the first patient for its Phase 2a clinical trial evaluating AKR-001, the company's lead product candidate for the treatment of NASH. -
NASH-focused Akero Therapeutics adds another $70M to the bank
December 26, 2018Just six months after bagging a $65 million series A, Akero Therapeutics is at it again. The company has reeled in $70 million in its B round that will push its lead asset.....
Pharma Sources Insight January 2025
